BRCA Breast Cancer Gene Doesn't Affect Survival

BRCA mutations are inherited and increase the risk of breast and ovarian cancers. Between 45 percent and 90 percent of women with a BRCA mutation develop breast cancer, compared with about 12.5 percent of women in the general population.
Source: WebMD Health - Category: Consumer Health News Source Type: news

Related Links:

AbstractEpidemiological studies show a reduced risk of breast cancer (BC) in women consuming high levels of long-chain (LC) omega-3 ( ω-3) fatty acids (FAs) compared with women who consumed low levels. However, the regulatory and mechanistic roles of dietary ω-6 and LC-ω-3 FAs on tumor progression, metastasis and survival are poorly understood. Female BALB/c mice (10-week old) were pair-fed with a diet containing ω-3 or an iso caloric, isolipidic ω-6 diet for 16 weeks prior to the orthotopic implantation of 4T1 mammary tumor cells. Major outcomes studied included: mammary tumor growth, surviva...
Source: Clinical and Experimental Metastasis - Category: Cancer & Oncology Source Type: research
Publication date: Available online 14 October 2018Source: Journal of Geriatric OncologyAuthor(s): Gabor Liposits, Kah Poh Loh, Enrique Soto-Perez-de-Celis, Lucy Dumas, Nicolò Matteo Luca Battisti, Sindhuja Kadambi, Capucine Baldini, Susana Banerjee, Stuart M. LichtmanAbstractBreast and ovarian cancer are common malignancies among older adults, causing significant morbidity and mortality. Although most cases of breast and ovarian cancer are sporadic, a significant proportion is caused by mutations in cancer susceptibility genes, most often breast cancer susceptibility genes (BRCA) 1 and 2. Furthermore, some breast an...
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
AbstractPurposeBRCA1 andBRCA2 genotyping results have clinical implications for cancer risk assessment and targeted therapy. Current practice in Israel is to genotype for the predominantBRCA1/2 mutations first, followed by full gene analysis in eligible mutation-negative individuals. This work assessed the rate of non-predominant mutations inBRCA1/2 in ethnically diverse high-risk cases.MethodsBreast and/or ovarian cancer patients who tested negative for the predominantBRCA1/2 mutations were referred for comprehensiveBRCA1/2 genotyping if calculated risk for carrying aBRCA mutation was ≥ 10%.ResultsOf 1258 eligible...
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
CONCLUSIONWe present an interesting case, of an accidentally revealed salpingeal carcinoma via RRSO in an asymptomatic young premenopausal woman.
Source: International Journal of Surgery Case Reports - Category: Surgery Source Type: research
University of Leicester researchers soon will open the first molecularly stratified clinical trial for malignant mesothelioma with the hope of moving the future of treatment toward more personalization. The phase II trial in the United Kingdom is designed to match therapy with a patient’s specific genetic profile. “We’re trying to bring the right drug to the right patient at the right time,” Professor Dean Fennell, chair of thoracic medical oncology at Leicester and chief trial investigator, told Asbestos.com. “We need to find different treatments that work for different people. This is a step...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
In this study, we explored the effect of HER2 on cancer stem cells induction and drug sensitivity of ovarian cancer cell lines. Firstly, we found that HER2 overexpression (HER2 OE) induced, while HER2 knockdown (HER2 KD) decreased CD44+/CD24- population. Consistently, HER2 expression was closely correlated with the sphere formation efficiency (SFE) of ovarian cancer cells. Secondly, we found that NFκB inhibition by specific inhibitor JSH23 or siRNA targeting subunit p65 dramatically impaired the induction of ovarian cancer stem cells by HER2, indicating that NFκB mediated HER2-induced ovarian cancer stem cells....
Source: Bioscience Reports - Category: Biomedical Science Authors: Tags: Biosci Rep Source Type: research
Evolutions and even revolutions are expected when the latest data in head and neck cancer, renal cell carcinoma, breast cancer, and ovarian cancer are presented at the leading European cancer meeting.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Krukenberg tumor, defined as metastatic adenocarcinoma to the ovary containing at least 10% signet ring cells, usually arises from the stomach but can also originate from other sites. We reviewed 17 metastatic breast carcinomas to the ovary with signet ring cells to potentially identify features indicative of mammary origin as opposed to other possible primary sites. The patients ranged from 41 to 76 (mean, 53.6) yr. Fourteen had a prior history of invasive breast carcinoma (invasive ductal carcinoma, 4; invasive lobular carcinoma, 3; adenocarcinoma not otherwise specified, 3; carcinoma with ductal and lobular featu...
Source: International Journal of Gynecological Pathology - Category: Pathology Tags: Pathology of the Upper Genital Tract: Original Articles Source Type: research
Breast cancer affects 1 in every 8 women during their lives, and is the second most common kind of cancer in women. No one knows why some women get breast cancer, but there are many risk factors. Risks that you cannot change include: Age – the risk rises as you get older. Genes – two genes, BRCA1 and BRCA2, greatly increase the risk. Women who have family members with breast or ovarian cancer may wish to be tested for the genes. Personal factors – beginning periods before age 12 or going through menopause after age 55. For the month of October, help save lives in your community by sharing quality h...
Source: NN/LM Middle Atlantic Region Blog - Category: Databases & Libraries Authors: Tags: Consumer Health Source Type: news
Abstract MiR-1204 has been recently identified as an oncogenic miRNA in breast cancer. Our study aims to investigate the role of miR-1204 in ovarian squamous cell carcinoma. Expression of miR-1204 and glucose transporter 1 in ovarian biopsies and plasma of both OC patients and healthy controls was detected by qRT-PCR. Correlations between patients' clinicopathological data were analyzed by Chi-square test. MiR-1204 overexpression OC cell lines were established. Expression of GLUT-1 protein was detected by western blot. Glucose uptake was measured by glucose uptake assay. Cell proliferation was detected by CCK-8 as...
Source: Bioscience, Biotechnology, and Biochemistry - Category: Biochemistry Authors: Tags: Biosci Biotechnol Biochem Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Genetics | Health | Ovarian Cancer | Ovaries | Women